Market Overview

Pfizer Settles Viagra Patent Litigation With Teva

Share:
Related PFE
The Top 10 Best-Selling Products In History
US Stock Futures Down Ahead Of Earnings
pSivida, Moore's Law, Pfizer, And The Next Regeneron (Seeking Alpha)

Pfizer (NYSE: PFE) announced that it has settled its litigation against Teva
Pharmaceuticals, USA Inc., relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil…

Pfizer Inc. announced that it has settled its litigation against Teva
Pharmaceuticals, USA (NASDAQ: TEVA), relating to Pfizer's patent covering the use
of Viagra® to treat erectile dysfunction (sildenafil citrate 25, 50, and
100 mg tablets), which expires in April 2020 (including pediatric
exclusivity). As a result of the settlement, Teva will be allowed to
launch a generic version of Viagra® in the United States on December 11,
2017, or earlier under certain circumstances. Teva will pay Pfizer a
royalty for a license to produce its generic version. The terms of the
settlement agreement are otherwise confidential. Teva has received
tentative approval from the U.S. Food and Drug Administration (FDA) for
its generic version of Viagra®.

See full press release

Posted-In: News Guidance Offerings Contracts Buybacks Legal Management Global

 

Related Articles (TEVA + PFE)

Around the Web, We're Loving...